Both tirzepatide and semaglutide can help you lose meaningful weight. The honest answer to which is better is that one tends to produce more weight loss, but the right one for you depends on your body, your tolerance, and your goals.
Said plainly: tirzepatide usually wins on the scale, but the best GLP-1 is the one you can actually stay on consistently.
How GLP's Work
Semaglutide is a GLP-1 receptor agonist. It mimics one gut hormone that signals fullness to your brain, slows how fast your stomach empties, and steadies blood sugar, so you eat less without white-knuckling it.
Tirzepatide does that too, and adds a second signal. It activates both GLP-1 and GIP receptors, a dual mechanism that appears to improve appetite control and insulin response beyond GLP-1 alone.
That means tirzepatide is pulling two metabolic levers where semaglutide pulls one.
What the head-to-head trial showed
For a long time we were comparing separate studies. Now there is a direct one. In the SURMOUNT-5 trial, adults on tirzepatide lost about 20% of their body weight at 72 weeks, compared with about 14% on semaglutide. That is roughly 47% more average weight loss, along with a bigger drop in waist circumference.
In a fair fight, tirzepatide produced more weight loss for the average person. One more detail that matters for real life: in that trial, gastrointestinal side effects led to stopping treatment more often with semaglutide than tirzepatide.
Side effects: they are more alike than different
Both medications share the same main side effects, and they are mostly gastrointestinal: nausea, constipation, diarrhea, and reflux, especially while your dose is increasing. For most women these are dose-dependent and fade as the body adjusts.
The most important variable is not which drug, it is how fast you titrate. There is no prize for rushing through nausea. The key here is ensuring your foundations are there. Some women simply tolerate one molecule better than the other, which is why the choice is not always about the bigger number.
Which one is right for you?
Tirzepatide is often the stronger choice if your priority is maximum weight loss and your body tolerates it well.
Semaglutide is a proven, effective option, available as an injection or an oral pill, and it may be the better fit depending on cost, preference, and how you respond.
Here is the part most comparisons skip: the medication is only part of the result. Without a protein target and resistance training, you can lose significant muscle alongside fat, and the results are far less durable. That is true for both molecules. That is why at Sesh Diagnostics, every weight loss prescription comes with complimentary training and nutrition guides inside our five-star app. The foundations are not optional to us.
Frequently asked questions
Is tirzepatide always better than semaglutide?
On average it produces more weight loss, but better depends on you. The best GLP-1 is the one you tolerate, can stay consistent with, and that fits your goals and budget. Some women do beautifully on semaglutide.
Can I switch from semaglutide to tirzepatide?
Often yes, under clinician guidance. Women who plateau or cannot tolerate one molecule's side effects sometimes do better after switching. The transition should be managed, not done on your own.
Will I regain the weight if I stop?
Some regain is common after stopping any GLP-1, which is why a maintenance plan and muscle-protecting habits matter from day one. This is the part SeshDx builds in from the start. The key is building a sustainable lifestyle, slowly. This isn't a race.
Do I still need to exercise and watch protein on these?
Yes. Both work best alongside adequate protein and resistance training. Without them you risk losing muscle, which hurts your metabolism and long-term results. Some women feel 'it isn't working' but in reality, the foundations aren't there for the GLP-1 to support.
This content is educational and is not medical advice. GLP-1 medications require a prescription from a licensed clinician. Individual results vary.
Sources:
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — NEJM
A Study of Tirzepatide in Participants With Obesity — ClinicalTrials.gov (NCT05822830)
